Enlivex Therapeutics Company
Enlivex is a clinical-stage macrophage reprogramming immunotherapy company that targets diseased macrophages in patients with sepsis.
Technology:
Cancer
Industry:
PharmTech
Headquarters:
Ness Ziona, HaMerkaz, Israel
Founded Date:
2005
Employees Number:
11-50
Funding Status:
IPO
Estimated Revenue:
$1M to $10M
Register and Claim Ownership